Radiotherapeutics Market Snapshot: This Sector Is Getting Hot
Executive Summary
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
You may also be interested in...
Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market
Bayer/Algeta’s Xofigo was cleared for castration-resistant prostate cancer patients with symptomatic bone metastases, but uptake of the radiotherapeutic will require referrals from most providers to a licensed radiation site and the company must find a way for the drug to be used instead of or in sequence with chemo and other prostate cancer therapies.
Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.